NEW YORK (GenomeWeb News) – Qiagen today said that it will collaborate with Bayer HealthCare on developing companion diagnostics for Bayer drugs with an initial focus on those that target solid tumors.

The companion diagnostic tests will run on Qiagen's QIA symphony automated instruments. In addition, the partners said that they will collaborate on developing technologies for patient profiling, which may result on research-use-only products for exploratory and translational medicine, said Qiagen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.